title: ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.
abstract: OBJECTIVE
  The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients.
  
  
  METHODS
  A total of 166 high risk stages II and III colon cancer patients were retrospectively enrolled in this study, and data were collected prospectively. They underwent a curative resection followed by FOLFOX4 adjuvant chemotherapy. We analyzed ERCC1 expression in the primary colon tumor by using immunohistochemical staining. The oncological outcomes included the 5-year disease-free survival (DFS) rate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model was used for the prognostic analysis.
  
  
  RESULTS
  ERCC1-positive expression was statistically significant in the older patients (P = 0.032). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).
  
  
  CONCLUSIONS
  We found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.
authors.affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Chee Young
authors.initials: CY
authors.lastname: Kim
authors.affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Sang Hyuk
authors.initials: SH
authors.lastname: Seo
authors.affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Min Sung
authors.initials: MS
authors.lastname: An
authors.affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Kwang Hee
authors.initials: KH
authors.lastname: Kim
authors.affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Ki Beom
authors.initials: KB
authors.lastname: Bae
authors.affiliation: Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Jin Won
authors.initials: JW
authors.lastname: Hwang
authors.affiliation: Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Ji Hyun
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Department of Pathology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Bo Mi
authors.initials: BM
authors.lastname: Kim
authors.affiliation: Department of Pathology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Mi Seon
authors.initials: MS
authors.lastname: Kang
authors.affiliation: Clinical Trial Center in Pharmacology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Min Kyung
authors.initials: MK
authors.lastname: Oh
authors.affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Kwan Hee
authors.initials: KH
authors.lastname: Hong
keywords: Colon neoplasms; ERCC1; FOLFOX